M&T Bank Corp trimmed its position in Icon Plc (NASDAQ:ICLR) by 2.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,601 shares of the medical research company’s stock after selling 1,019 shares during the period. M&T Bank Corp’s holdings in Icon were worth $4,859,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. CWM LLC boosted its stake in Icon by 211.8% in the fourth quarter. CWM LLC now owns 212 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 144 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in Icon by 36.6% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the medical research company’s stock valued at $56,000 after acquiring an additional 116 shares in the last quarter. Rehmann Capital Advisory Group boosted its stake in Icon by 75.5% in the third quarter. Rehmann Capital Advisory Group now owns 416 shares of the medical research company’s stock valued at $64,000 after acquiring an additional 179 shares in the last quarter. Tributary Capital Management LLC acquired a new stake in Icon in the fourth quarter valued at approximately $74,000. Finally, DekaBank Deutsche Girozentrale boosted its stake in Icon by 119.7% in the third quarter. DekaBank Deutsche Girozentrale now owns 769 shares of the medical research company’s stock valued at $113,000 after acquiring an additional 419 shares in the last quarter. Institutional investors own 88.86% of the company’s stock.
NASDAQ:ICLR opened at $139.37 on Friday. Icon Plc has a 12 month low of $104.85 and a 12 month high of $155.33. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.17 and a quick ratio of 2.17. The firm has a market cap of $7.56 billion, a PE ratio of 25.86, a P/E/G ratio of 1.75 and a beta of 0.71.
Several equities research analysts have recently commented on the stock. BidaskClub upgraded shares of Icon from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 1st. Zacks Investment Research downgraded shares of Icon from a “hold” rating to a “sell” rating in a research note on Wednesday, October 24th. UBS Group set a $136.00 price objective on shares of Icon and gave the stock a “sell” rating in a research note on Saturday, October 27th. Goldman Sachs Group downgraded shares of Icon from a “conviction-buy” rating to a “buy” rating and set a $168.00 price objective for the company. in a research note on Friday, December 14th. Finally, Evercore ISI upgraded shares of Icon from an “in-line” rating to an “outperform” rating in a research note on Friday, October 26th. Two research analysts have rated the stock with a sell rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $153.11.
WARNING: This story was originally published by Macon Daily and is owned by of Macon Daily. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://macondaily.com/2019/02/09/icon-plc-iclr-holdings-trimmed-by-mt-bank-corp.html.
ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Article: No Load Funds
Want to see what other hedge funds are holding ICLR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Icon Plc (NASDAQ:ICLR).
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.